← Back to scoreboard
HealthcareJNJ
Johnson & Johnson
Operates across pharma and MedTech with two AI adoption tracks. Isomorphic Labs partnership is headline AI drug discovery bet. Ottava surgical robotics and 6,000 digital specialists signal serious intent.
AI Impact Score
7.1/10
↑ Positive
Scoring Breakdown
Sector Base
7
AI Revenue Exposure
7
Moat Durability
8
Disruption Risk (lower=better)
4
AI Adoption Maturity
8
Scenarios
Bull Case
Diversification across pharma and MedTech reduces single-bet AI risk. Isomorphic deal covers cross-modality targets positioning J&J for AlphaFold 3-era breakthroughs.
Bear Case
Size creates AI coordination risk across two divisions with different regulatory pathways. Isomorphic deal puts AI design responsibility at third party.
Key Factors to Watch
- ●Isomorphic Labs partnership covers multi-target, multi-modality drug design
- ●MedTech AI (Ottava robotics, Volt PFA cardiac) creates revenue diversification
- ●6,000 digital/data specialists hired — AI is infrastructure, not a project
Score History
| Date | Score | Direction | Note |
|---|---|---|---|
| 2026-03-08 | 7.1 | Positive | Score 7.2→7.1 (formula reweight: sb 0.25→0.15, are 0.20→0.25, md 0.20→0.25, dr 0.20→0.25, aam 0.15→0.10) |
| 2026-03-08 | 7.2 | Positive | Score 7.0->7.2 (aam 7->8). External research cross-ref: only company with deep AI across both pharma AND MedTech, 6K data scientists, OTTAVA + Monarch + VELYS + Polyphonic ecosystem |
| 2026-03-08 | 7.0 | Positive | Initial assessment from batch 3 research |
Healthcare Peers
Last researched: 2026-03-20
This is research and analysis, not financial advice. Scores reflect AI impact potential, not investment recommendations.